Literature DB >> 1326846

Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. II: Reduced dose of low molecular weight heparin.

E Borstad1, K Urdal, G Handeland, U Abildgaard.   

Abstract

In a double blind, randomized trial the hemorrhagic complications of a reduced dose of low molecular weight heparin (LMWH) (Fragmin, KabiPharmacia) were compared to those of the conventional dose of unfractionated heparin (UH). 2500 anti-XaU of LMWH was given once daily and UH in a dose of 5000 anti-XaU twice daily. During a one year period 141 patients undergoing gynecological surgery were included in this study. The patients were examined clinically for hematomas and for deep venous thrombosis (DVT) on the third and fifth day. Venography was performed when DVT was suspected. No patients developed clinical DVT. One woman in the LMWH group had pulmonary embolism 3 days after the prophylaxis was stopped. Two women in the LMWH group died, one from a stroke on day 2, one from cancer on day 39. There was no significant difference in serious bleeding complications between the two regimens, 20% in the LMWH group and 14% in the UH group. Even with the reduced dose of LMWH the mean plasma concentration of heparin in the LMWH group was higher (mean 0.14 anti-XaU/ml) than in the UH group (0.029 anti-XaU/ml) 3 hours after injection on the 2nd postoperative day. A reduced dose of LMWH (2500 anti XaU once daily) does not cause more bleeding complications than the conventional heparin regimen to prevent thrombosis, as was the case in our previous study with 5000 anti XaU of LMWH once daily.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1326846     DOI: 10.3109/00016349209021097

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  4 in total

1.  American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients.

Authors:  David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm
Journal:  Blood Adv       Date:  2019-12-10

Review 2.  Efficacy of intermittent pneumatic compression for venous thromboembolism prophylaxis in patients undergoing gynecologic surgery: A systematic review and meta-analysis.

Authors:  Jian-Ping Feng; Yu-Ting Xiong; Zi-Qi Fan; Li-Jie Yan; Jing-Yun Wang; Ze-Juan Gu
Journal:  Oncotarget       Date:  2017-03-21

Review 3.  Anticoagulation for perioperative thromboprophylaxis in people with cancer.

Authors:  Charbel F Matar; Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Itziar Etxeandia-Ikobaltzeta; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2018-07-11

4.  Comparison of Efficacy and Safety of Two Different Enoxaparin Products in Prevention of Venous Thromboembolism Following Major Obstetric-gynecological Surgeries: An Open-label Randomized Clinical Trial.

Authors:  Manoochehr Abdolvand; Ashraf Aleyasin; Mohammad Reza Javadi; Mohammad Solduzian; Seyed Hossein Hosseini; Zohreh Ziaei; Samira Samira; Kheirollah Gholami
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.